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Abstract
Colorectal cancer (CRC) has one of the highest incidences among all cancers. The majority of CRCs are sporadic cancers that
occur in individuals without family histories of CRC or inherited mutations. Unfortunately, whole-genome expression studies
of sporadic CRCs are limited. A recent study used microarray techniques to identify a predictor gene set indicative of
susceptibility to early-onset CRC. However, the molecular mechanisms of the predictor gene set were not fully investigated
in the previous study. To understand the functional roles of the predictor gene set, in the present study we applied a
subpathway-based statistical model to the microarray data from the previous study and identified mechanisms that are
reasonably associated with the predictor gene set. Interestingly, significant subpathways belonging to 2 KEGG pathways
(focal adhesion; natural killer cell-mediated cytotoxicity) were found to be involved in the early-onset CRC patients. We also
showed that the 2 pathways were functionally involved in the predictor gene set using a text-mining technique. Entry of a
single member of the predictor gene set triggered a focal adhesion pathway, which confers anti-apoptosis in the early-onset
CRC patients. Furthermore, intensive inspection of the predictor gene set in terms of the 2 pathways suggested that some
entries of the predictor gene set were implicated in immunosuppression along with epithelial-mesenchymal transition
(EMT) in the early-onset CRC patients. In addition, we compared our subpathway-based statistical model with a gene set-
based statistical model, MIT Gene Set Enrichment Analysis (GSEA). Our method showed better performance than GSEA in
the sense that our method was more consistent with a well-known cancer-related pathway set. Thus, the biological
suggestion generated by our subpathway-based approach seems quite reasonable and warrants a further experimental
study on early-onset CRC in terms of dedifferentiation or differentiation, which is underscored in EMT and
immunosuppression.
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Introduction
Familial adenomatous polyposis (FAP) and hereditary nonpol-
yposis colorectal cancer (HNPCC) are autosomal dominant
diseases that result from inherited genetic mutations in adenoma-
tous polyposis coli (APC) and mismatch repair genes [1]. However,
these diseases account for only 25% of the total number of
colorectal cases in the United States in 2010 [2]. The remaining
75% of cancers are reportedly sporadic colorectal cancers (CRCs)
without family histories [2] (www.cancer.gov), for which the
mechanism is still not clear [3].
Hong et al. [3] identified 7 highly upregulated genes (CYR61,
EGR1, FOSB, FOS, VIP, UCHL1, KRT24) in early onset sporadic
CRC patients that were used as a predictor gene set assessed with
a microarray technique. For their experiments, normal-appearing
mucosa adjacent to tumor was obtained from the CRC patients
and normal mucosa was obtained from healthy controls. They also
provided a discussion on signaling pathways (MAP kinase (MAPK)
signaling, NFAT-immune signaling, hypoxia signaling, insulin
signaling, PI3K-AKT signaling, Wnt signaling, G protein-coupled
receptor (GPCR) signaling).
In the present study, we further explored the microarray dataset
in order to add a potential upstream regulator of some of the
enumerated signaling pathways in the early-onset CRC patients
assessed in the Hong et al. study [3]. Specifically, we performed
advanced statistical analysis to enhance the molecular understand-
ing of the predictor gene set using text-mining and significant
subpathways related to the early-onset CRC cases.
Our approach involves public text-mining [4] using a new
statistical model that handles regulation (e.g., inhibition, activa-
tion) among biological entries, and performs a permutation test for
subpathway identification of a given pathway. We first identified
statistically significant subpathways related to the early onset
CRCs from KEGG pathways [5] with the model, and subse-
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among the predictor gene set and some representative significant
subpathways.
Our proposed model suggests that early-onset CRC is involved
in subcomponents of the focal adhesion pathway and the natural
killer (NK) cell-mediated cytotoxicity pathway. The NK cell-
mediated cytotoxicity pathway in particular hints at the presence
of immune cells in the early-onset CRC patients, which implies
paracrine communication between immune cells (e.g., NK cells, T
cells, NK T cells) and various other cells [6]. In addition, our result
indicates that the previously reported signaling pathways (Wnt,
PI3K-AKT, MAPK) [3] are likely cascaded through their
upstream focal adhesion kinase (FAK), [7] which belongs to the
focal adhesion pathway. Therefore, FAK [7] may be a valuable
therapeutic target candidate for the early-onset CRC predictor
gene set diagnosis. Furthermore, our text-mining analysis of the 2
pathways along with the predictor gene set implied that some
elements of the predictor gene set are involved in cell survival and
epithelial-mesenchymal transition (EMT) [8,9,10] through the
focal adhesion pathway and immunosuppression [8,10,11].
Results
Overview
The main concept of our statistical model was to pinpoint
statistically significant subpathways whose expression (e.g., micro-
array) agreed with the regulation information (e.g., activation,
inhibition) (Figure 1A) in the KEGG pathway database. Our
approach is briefly described here.
The non-metabolic KEGG pathways were reduced into linear
subpathways, as described in the Materials and Methods (Figure 2). In
this study, the term ‘‘linear subpathway’’ is used equivalent to
‘‘subpathway’’. We then selected well-defined subpathways in
which the gene expression agreed with the regulation information
under the set rules (Figure 1A) as candidates for measuring their
statistical significance (see Materials and Methods). A statistic S for
Figure 1. Rules and schematic diagram for the statistical model. A. Rules for matching an edge of two adjacent entities in KEGG pathways
with their gene expression changes. Given an edge, gene 1 is called a source node of which the edge goes out, and gene 2 a sink node of which the
edge comes in. B. Schematic diagram of the statistical model. Given a subpathway, the longest segment (well-defined subpathway) from the leaf
node was identified. A statistic S for the well-defined subpathway was calculated. The null distribution of S was obtained via 1,000,000 sample label
permutations and the p-value for the observed S was finally calculated (see Materials and Methods for details). Red ovals are up-regulated in the
cancer patients, and green ones down-regulated.
doi:10.1371/journal.pone.0031685.g001
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evaluated by computing the empirical p-value via sample label
permutations (Figure 1B).
A total of 90 KEGG pathways were broken down into over 130
million extensive linear subpathways that considered all multiple
gene assignments. Among these subpathways, 4,644 well-defined
subpathways were identified and their significance evaluated via
permutation tests. Subsequently, text-mining association analysis
was performed for the selected significant well-defined subpath-
ways; further discussion on their functional roles is provided
hereafter.
Significant well-defined subpathways
We performed multiple comparison tests by controlling the false
discovery rate (FDR) [12]. The FDR q-values were computed
using the p-values by performing 1 million permutation tests
(Figure S1). The p-value that corresponded to an FDR of 5% was
0.01386, which yielded 1,289 significant well-defined subpath-
ways. Since we opted not to provide detailed biological
interpretation of all of these significant well-defined subpathways,
we focused on examination of the top 30% of these well-defined
subpathways to provide a more detailed biological description.
The majority of the selected subpathways we discuss belong to 6
KEGG pathways (Figure S2): Focal adhesion (KEGG hsa04510),
Pathways in cancer (KEGG hsa05200), NK cell-mediated cytotox-
icity (KEGG hsa04650), MAPK signaling pathway (KEGG
hsa04010), Wnt signaling pathway (KEGG hsa04310), and Neu-
trophin signaling pathway (KEGG hsa04722). For the functional
discussion and visualization, we mapped functionally interesting well-
defined subpathways (Table S1) of the 6 KEGG pathways into
KEGG pathway diagrams (Figures 3 and 4; Figures S3, S4, S5, and
S6). In particular, we focused on 3 pathways (Focal adhesion, NK
cell-mediated cytotoxicity, Pathways in cancer) that had not been
explicitly mentioned in the previous Hong et al. study [3]. The gene
entries of the well-defined subpathways included in the functional
discussion and visualization of the 3 pathways are summarized in
Table 1.
Validation of the significant well-defined subpathways
We validated the entries in Table 1 by using an independent
MedLine text-mining tool [4], PubGene. The purpose of this was
to confirm whether the literature supported direct co-occurrences
between the term ‘‘colorectal cancer’’ and the entries in Table 1.
We found that 79% of the entries in Table 1 had direct
interactions in the PubGene analysis (Table S2). Thus, we
concluded that our model results provided a reasonable agreement
with the literature examined.
Pathways in cancer (hsa05200)
The KEGG pathway hsa05200 (pathways in cancer, Figure S3)
is self-evident. Growth factor signaling, Wnt signaling, and MAPK
signaling, which are located in the left part of Figure S3, were
activated in the samples from CRC patients. The signals are
common driving forces during carcinogenesis [8,13]. Apparently
normal mucosa in the CRC patients has an intrinsic potential for
further transformation.
Focal adhesion pathway (hsa04510)
Figure 3 shows the focal adhesion pathway. This result indicates
that the bottom part of the pathway is highly involved with the
Figure 2. Overview of our study.
doi:10.1371/journal.pone.0031685.g002
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from its upstream receptors but also a source node toward its
downstream signaling transductions (Wnt, PI3K-AKT/PKB, and
MAPK signals) for survival. PTEN (Table 1) [14], a tumor
suppressor and antagonizer of the PI3K-AKT/PKB signaling
pathway, was downregulated in the focal adhesion pathway in the
analysis of the CRC patients’ samples compared with that of the
healthy controls’ samples.
Hong et al. [3] suggested that the Wnt signaling pathway is
involved in CRC patients. Our result regarding the focal adhesion
pathway (Figure 3) supports the view that GSK-3b (GSK3B,
Table 1) regulated by PI3K-AKT/PKB signaling of FAK
downstream was downregulated in the CRC patients, and also
that b-catenin (CTNNB1, Table 1) was highly expressed by
downregulation of the Wnt signaling inhibitor GSK-3b in the
CRC patients. Upon looking further into the information in Figure
S5, we determined that gene expression of various activators and
inhibitors related to Wnt signaling activation is consistent with the
regulation flows. Another pathway, MAPK signaling (Figure S4)
that was upregulated in the CRC patients is also located
downstream of FAK (Figure 3).
Since the 3 activated signals (Wnt, PI3K-AKT/PKB, and
MAPK signals) are located downstream of FAK belonging to the
focal adhesion pathway, FAK [7,15] may be a therapeutic target
for the early-onset CRC predictor gene set diagnosis. Further-
more, because the crucial roles of Wnt, PI3K-AKT/PKB, and
MAPK signaling shed light on EMT [9], there has been gradually
increasing importance placed on FAK.
Interestingly, CYR61, which was included in the predictor gene
set, is a ligand of ITGB5 (aVb5 integrin, denoted as ITGB in
Figure 3), according to the KEGG BRITE database [5]. Figure 3
shows that CYR61 is one of the far upstream cues that triggers
FAK, implying that FAK subsequently activates 3 signals: Wnt,
PI3K-AKT/PKB, and MAPK signaling. Recently, Wnt, PI3K-
AKT/PKB, and MAPK signals were shown to be involved in
EMT [9], and apparently normal mucosa in CRC patients could
undergo phenotypical transformation by these 3 signals via the
CYR61-FAK axis. In other words, some cells in the normal-
appearing mucosa in the CRC patients may be close to atypical
cells by utilizing EMT. We will describe the evidence of EMT in
terms of gene expression level and explore any possible association
between the predictor gene set and EMT in the Discussion.
Another finding relevant to the downstream region of the focal
adhesion pathway is that the anti-apoptosis protein c-IAP (BIRC3,
Table 1) [16], which is a negative regulator of caspases (e.g.,
CASP3, CASP8, CASP9), was also upregulated in the CRC
patients. Thus, we further examined the various downstream c-
IAPs (cellular inhibitor of apoptosis) in the focal adhesion pathway,
where c-IAPs along with survivin (BIRC5) are also important anti-
apoptotic proteins. Of note, it has also been shown that the c-IAPs
and survivin also inhibit downstream caspases of both extrinsic
and intrinsic apoptotic pathways [16]. We found that the majority
of c-IAPs were upregulated in the CRC patients (Table 2). Thus,
the focal adhesion pathway may confer inhibition of caspase
activity upon the tumorigenesis of potential atypical cells in
apparently normal mucosa.
NK cell-mediated cytotoxicity pathway (hsa04650)
Our statistical analysis indicated significant agreement between
the gene expression of the CRC patients and part of the immune
pathway (hsa04650, Figure 4), which implies the presence of other
immune cells as well as NK cells in the CRC patients’ specimens.
FAS in the target cells of NK cells and its ligand (FASLG),
which is produced by NK cells, were highly expressed in the CRC
patients’ samples. High FASLG expression in the CRC patients
complies with previous clinical observations [6,17] in which high
FASLG expression was correlated with high incidences of
metastases and poor survival in colorectal carcinoma patients
and in other carcinoma patients.
In the apparently normal mucosa of the CRC patients, various
target cells including potentially atypical cells may survive from
FASLG-FAS death receptor signaling by escaping either extrinsic
or intrinsic apoptotic signaling. In fact, the apoptotic signals were
inhibited in the CRC patients because the c-IAPs [16] that
inhibited caspases were upregulated in the CRC patients in terms
of gene expression (Tables 1 and 2). Another possibility is that
FASLG upregulation by target cells, including potentially atypical
cells, might initiate fratricide and suicide among the immune cells
with FAS beneficial for transformation of potentially atypical cells.
However, the existence of high interferon-gamma (IFN-c)
expression secreted by NK cells or immune cells in CRC patients
remains controversial because NK cell cytotoxicity is traditionally
believed to control immunosurveillance over cancer and atypical
cells. Recently, a significant relationship between anti-tumor
immunity and survival of cancer cells has been reported [6,18].
Furthermore, IFN-c is known to be involved in immunosurveil-
lance against cancer cells, in multiple phenotypic effects on
somatic cells (e.g., cell cycle progression, proliferation, cell
differentiation, transformation), and in cancer cell escape
[11,18,19,20]. Thus, in the Discussion, we describe other roles of
IFN-c, especially in terms of the way cancer cells or potentially
atypical cells in CRC patients could adjust the local immune
system via immunosuppression in order to escape from immuno-
surveillance.
Association among focal adhesion, NK cell-mediated
cytotoxicity, and the early-onset CRC predictor gene set
As mentioned in the text above, Hong et al. [3] reported that
early-onset susceptibility was attributed to the upregulated gene set
called the ‘‘predictor gene set’’ in CRC patients that consists of
CYR61, EGR1, FOSB, FOS, VIP, UCHL1, and KRT24.W e
inspected the associations among the genes listed in Table 1 and
the predictor gene set with the text-mining tool, PubGene [4]
(www.pubgene.org) (Figure S7). The input in the tool consisted of
the predictor gene set, focal adhesion (FAK, ITGB5), and NK cell-
mediated cytotoxicity (INFG, FAS, FASLG). Figure 5 shows an
association network for the input genes in CRC. We already
mentioned that b-catenin (CTNNB1, Wnt pathway in Figure 5)
was regulated by FAK in focal adhesion. The predictor gene set,
focal adhesion, and NK cell-mediated cytotoxicity were highly
associated with each other in CRC.
Comparison of our method with Gene Set Enrichment
Analysis (GSEA) of the Hong et al. dataset
We compared the KEGG pathways containing significant well-
defined subpathways identified by our method with those KEGG
pathways obtained from the GSEA JAVA web start program
(default options with 5,000 permutations). In our method, the
significance level (p-value) was 0.05 for the cutoff of the well-
Figure 3. Mapping of the entries of the well-defined subpathways into the focal adhesion pathway. If the fold-change of the cancer
patient group over the healthy control group is greater than one the gene is red, otherwise green. See Table 1 and Table S1 for detailed information.
doi:10.1371/journal.pone.0031685.g003
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GSEA method. Our method reported 1,966 significant well-
defined subpathways that corresponded to 78 KEGG pathways.
The GSEA program reported 2 broad types of significant
pathway lists: 10 activated pathways and 30 repressed pathways
in the CRC patients. The number of overlapping pathways
between the 2 methods was 6, which is not surprising when
considering the differences between 2 methods. Nevertheless, it is
interesting that the 2 methods identified 6 common cancer-
associated pathways.
To compare the 78 pathways identified by our method with the
40 pathways identified by GSEA, we used the cancer-related
pathways reported by Vogelstein et al. [13] as a gold standard.
That is, we inspected which method provided more path-
ways consistent with the cancer-related pathways identified by
Vogelstein et al. The cancer-related pathways from the Vogelstein
et al. study were manually mapped to their corresponding KEGG
pathways because KEGG pathway identifiers corresponding to
the cancer-related pathways were not mentioned explicitly in
the study. We then inspected the overlapping pathways be-
tween the Vogelstein cancer-related KEGG pathways and
those identified by the 2 methods. As shown in Table S3, our
method provided more consistent results with the cancer-related
pathways identified in Vogelstein et al. than did the GSEA
method. Further details on this section are described in the
Appendix S1.
Comparison between the pathway substructure of the
Hong et al. dataset and that of the other dataset
To determine how closely the pathway substructure of the Hong
dataset overlaps with that of an additional colorectal dataset, we
searched for an additional colorectal dataset from Gene Expression
Omnibus (GEO). Although there are several datasets for CRC, it
seems no datasets are available relating to a comparison of early-
onset colorectal cancer patients with healthy controls, as is carried
out in the Hong et al. study. Fortunately, we found the dataset
GSE4183 [21], which compares various colorectal diseases
(colorectal carcinoma, colorectal adenoma, inflammatory bowel
diseases) with normal controls in a more general setting (www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4183). From the
Table 1. The gene entries of the well-defined subpathways
used for visualizing the three pathways diagrams (Figures 3
and 4, Figure S3).
Focal adhesion
NK cell
cytotoxicity Pathways in cancer
AKT1 1.297 ARAF 4.631 ARAF 4.631
BIRC3 (c-IAP-2) 2.201 CSF2 1.879 BCR 1.241
CAV1 3.937 FAS 3.374 CCND1 1.180
CCND3 1.559 GRB2 1.613 CDK4 1.315
CTNNB1 (b-catenin) 2.562 HLA-B 0.795 CTNNB1 (b-catenin) 2.562
ELK1 2.593 HLA-C 0.655 DAPK1 0.438
FYN 4.286 HLA-G 0.693 DVL3 1.608
GRB2 1.613 HRAS 1.027 ETS1 1.805
GSK3B 0.735 IFNG 1.322 FGF13 5.486
HRAS 1.027 IFNGR1 2.086 FGFR1 2.138
IGF1 2.529 KIR2DL3 0.632 FIGF 3.458
ILK 1.467 KIR3DL2 0.721 FLT3 1.262
ITGB5 1.431 LAT 1.781 FLT3LG 3.022
JUN 4.179 LCP2 2.682 FOS 36.201
MAP2K1 1.162 MAP2K1 1.162 FZD10 6.256
MAPK1 2.425 MAPK1 2.425 GRB2 1.613
MAPK8 2.355 PTPN11 0.417 GSK3B 0.735
PAK3 2.780 SOS1 1.624 HRAS 1.027
PDGFRB 2.851 TNF 1.009 IGF1 2.529
PIK3CG 3.224 FASLG 2.096 IGF1R 2.299
PRKCA 3.061 IL8 4.276
PTEN 0.599 JUN 4.179
PTK2 2.151 KIT 1.430
RAC2 2.502 MAP2K1 1.162
RAF1 1.813 MAPK1 2.425
SHC3 1.838 MAPK8 2.355
SOS1 1.624 MMP2 3.031
VAV1 1.945 MYC 3.052
CYR61 80.630 NTRK1 1.225
PDGFB 5.234
PDGFRB 2.851
RALGDS 1.478
RET 2.212
RHOA 4.286
SOS1 1.624
TCF7L1 2.735
WNT3 3.147
The number represents the fold change of groups the CRC patient over the
control. The genes CYR61 and FASLG were not reported in the statistical
analysis but were added, considering their contexts in the pathways.
doi:10.1371/journal.pone.0031685.t001
Figure 4. NK cell mediated cytotoxicity. Same description as Figure 3.
doi:10.1371/journal.pone.0031685.g004
Table 2. The gene expressions of c-IAPs, survivin (BIRC5) and
XIAP (BIRC4).
Genes Control
1 Cancer
1,2 Fold-change
3
BIRC1 6.998 7.032 1.024
BIRC2 12.570 12.070 0.707
BIRC1///LOC648984///LOC653371 7.597 7.979 1.303
BIRC1///LOC653371 7.806 7.962 1.114
BIRC5 7.773 7.112 0.632
BIRC7 7.720 7.757 1.026
BIRC4 11.741 10.915 0.564
BIRC4BP 9.973 11.090 2.169
BIRC3 8.456 9.594 2.201
BIRC6 9.315 9.864 1.463
The majority of them except BIRC2, BIRC5, and BIRC4 were overexpressed in the
cancer patients.
1The value is the median of log2-scaled expressions of the group.
2It is the normal-appearing mucosa in the CRC patients.
3It represents fold-change of the cancer group over the control group.
doi:10.1371/journal.pone.0031685.t002
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and colorectal carcinomas (n=15). The GSE4183 dataset was
analyzed with our method, which revealed 3,669 well-defined
subpathways (identified from ,130 million subpathways) upon
determining their significance based on 100,000 sample permu-
tation tests. Furthermore, the comparison between the GSE4183
dataset and the dataset from Hong et al. (GSE4107) showed that
250 well-defined subpathways overlapped between the 2 datasets.
To determine how well these 2 results coincided with each other,
we also performed Fisher’s exact test based on the randomization
model. The p-value from the hypergeometric distribution was less
than 2.2e-16, implying that the 2 results coincided well with each
other. Thus, we conclude that our finding relevant to Hong’s
pathway substructure is well supported by our finding from the
other independent dataset. Further details on this section are
described in the Appendix S1.
Discussion
Our novel analysis suggests the following results: 1) The subsets
from focal adhesion, pathways in cancer, and NK cell-mediated
cytotoxicity are highly involved in early-onset sporadic CRC
patients; and 2) Surprisingly, the text-mining analysis suggested
that the molecular function of the predictor gene set for early-onset
sporadic CRCs is associated with focal adhesion and NK cell-
mediated cytotoxicity. In the text below, we discuss the potential
molecular mechanisms of this association in terms of immuno-
suppression and EMT.
Immunosuppression
The recent literature [6,11,18,19,22,23,24] has set up a
conceptual framework in which interactions between tumor and
immunity are thought to help a number of cancer cells escape
from immune-raiding by undergoing the following 3 phases in a
linear or mixed manner: elimination (immunosurveillance),
equilibrium (tumor dormancy), and escape (immunosuppression).
In particular, cancer cell escape by immunosuppression
[6,8,11,19,25,26] has been extensively studied, and 2 types of
immunosuppressive cells are thought to negatively regulate anti-
tumor immune response: regulatory T cells (TReg) and myeloid-
derived suppressor cells (MDSCs) [8,11,27,28]. We discuss below
the roles of IFN-c, other cytokines, and the predictor gene set in
terms of these 2 types of immunosuppressive cells in early-onset
CRC patients.
It has been demonstrated previously that IFN-c can induce
activation and expansion of MDSCs in colon cancer [28], and that
activated MDSCs not only inhibit effector T cell activity/proliferation
but also induce immunosuppressive CD4
+CD25
+Foxp3
+ TReg cells
from CD4
+CD25
2 T cells [6,11,28]. TReg cells, which also express
CTLA-4, PD-1, and PD-L1 on their cell surfaces, positively regulate
immunosuppressive cytokines interleukin (IL)-10 and tumor growth
factor-beta (TGF-b), which can also induce TReg differentiation
[6,11,29]. Since TReg cells are found in tumor infiltrating lymphocytes
(TILs) in various cancers [6,11,29], the apparently normal mucosa in
the CRC patients might have TILs present with immunosuppressive
activity. ARG1 is also a key metabolic enzyme for MDSCs to
negatively regulate lymphocyte functions by consuming or sequester-
ing the amino acid arginine that is critical for T cell function. Thus, we
inspected the gene expression levels of the examined genes (CD4,
CD25, FOXP3, TGF-b,I F N - c, IL-10, CTLA-4, PD-1, PD-L1,
ARG1) in the CRC patients and confirmed they were all upregulated
in the cancer patients (Table 3).
To provide gene expression-level evidence of the presence of
MDSCs in CRC patients, we inspected (directly or indirectly)
Figure 5. The association network of the susceptible gene set from Hong et al. and several representative genes from Table 1. The
three green boxes represent the gene set (CYR61, FOS, FOSB, UCHL1, VIP, EGR1, KRT24), NK cell mediated cytotoxicity (IFNG, FAS, FASLG), and Focal
adhesion (PTK2) from left to right. The options used in the network are described in Figure S7. The pale blue-filled boxes represent Mesh (www.nlm.
nih.gov/mesh/) Diseases terms for the genes. It is noted that ITGB5 associations did not appear in the PubGene result.
doi:10.1371/journal.pone.0031685.g005
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(ITGAM), CD33, CD34, and CD15 [6]. Of note, we examined
FUT4 and FUT9 instead of CD15 because CD15 is not a protein
but an antigen synthesized by FUT4 and FUT9 [30]. We found
that all of the markers except FUT4 were upregulated in the
cancer patients (Table 3).
It has been shown previously that cancer cells expressing PD-L1
on their surface secrete immunosuppressive cytokines Galectin-1,
IL-6, IL-10, and TGF-b, which can inhibit cytotoxic CD8
+ T cells
[11]. Furthermore, the cancer cells producing higher levels of
indoleamine 2,3-dioxygenase (IDO) can prevent invasion of NK
cells and effector T cells by depleting tryptophan essential for T
cell function [6,11]. In the present study, we confirmed a higher
expression level of the examined genes (for PD-L1, Galectin-1, IL-
6, IL-10, IDO, and TGF-b) in the cancer patients (Table 3).
The gene expression analysis shown in Table 3 suggests that
immunosuppressive activity is highly observed in apparently normal
mucosa. This finding could provide additional information about a
‘‘field change’’ [31], which refers to proliferation and anti-apoptotic
activity in the apparently normal mucosa adjacent to tumor. In other
words, anti-apoptosis of the field change could also benefit from
immunosuppression by escaping the immune-raid.
To look furtherforfunctional refinementof the predictorgene set
in terms of immunosuppression, we fed the predictor gene set into
PubGene [4] with the MeSH (www.nlm.nih.gov/mesh) term
‘‘immunosuppression’’ (descriptor ID: D007165). The result (data
notshown)obtainedatthetimeofmanuscriptpreparationindicated
that 4 genes(EGR1, FOS,UCHL1,a n dVIP) haveanassociation with
immunosuppression according to the literature. Based on a review
by Ganea et al., which was suggested by PubGene, VIP (a well-
known immunoregulatory neuropeptide) inhibits the secretion of
proinflammatory cytokines and induces TReg cells [32]. Other
recent studies also support the immunosuppressive roles of VIP
[33,34] because VIP relieves collagen-induced arthritis and
sarcoidosis by inducing CD4
+CD25
+Foxp3
+ TReg cells from
CD4
+CD25
2 T cells. VIP is also involved in immune privileges
in the eye by inhibiting T lymphocyte activation and proliferation
[35]. Thus, high VIP expression in CRC patients may pinpoint
another major immunoregulatory cytokine in our analysis.
EMT
We also inspected the expression level of EMT-related genes
[9,36], including matrix proteases, invasion molecules, epithelial/
mesenchymal markers,and E-cadherin repressors.We found that the
majority of them were upregulated in the cancer patients (Table 4).
Therefore, the EMT [9] process can take place in the cancer patients,
at least in terms of gene expression. This finding is unexpected in that
atypical or precancerous cells could exist even in the normal
appearing mucosa by cell morphology changes (e.g., EMT).
To explore the potential roles of the predictor gene set, we input
the predictor gene set into PubGene [4] with the MeSH term
‘‘Epithelial-Mesenchymal Transition’’ (descriptor ID: D058750).
At the time of the manuscript preparation, 3 genes (EGR1, FOS,
CYR61) out of the predictor gene set were found in the literature to
have an association with EMT.
In particular, we paid attention to the gene CYR61 because
CYR61 is a ligand that can trigger a focal adhesion pathway.
Monnier et al. [37] demonstrated that CYR61-aVb5 integrin-
induced metastasis was involved in the tumor bed effect after
radiotherapy upon utilizing HCT116 CRC cell derivatives in
hypoxic conditions. Additional recent studies on CYR61-driven
development of cell motility in pancreatic ductal adenocarcinoma
and in gastric epithelial cells [38,39] indicate that CYR61 is one of
the key molecules for EMT that could confer metastatic ability and
cell motility to a primary tumor. Thus, CYR61 may be one of the
driving molecules for enhancing EMT-related pathways (Wnt and
PI3K/AKT signals) [9,40] in early-onset CRC patients via the
CYR61-FAK axis (Figure 3).
Another interesting finding we made upon examining the
relationship between EMT and the predictor gene set was VIP,
which was recently reported to induce EMT with the stimulation
of matrix proteases matrix metalloproteinase (MMP)-2 and MMP-
9 in prostate tumorigenesis [41]. We found that gene expression of
these 2 proteases was indeed upregulated in the cancer patients
(Table 4).
Cytokines commonly involved in both EMT and
immunosuppression
Because we found VIP is a cytokine involved in both EMT and
immunosuppression, our finding implies paracrine signaling
between immune cells and various target cells is involved in both
processes. We also found an additional cytokine involved in the 2
processes, in that immunosuppressive TGF-b (TGFB1; Table S5)
[22,29,36,42] is a well-known EMT inducer [9,43]. Indeed, we
found that the majority of TGF-bs and their receptors were
upregulated in the CRC patients.
Conclusion
Our gene expression data analysis suggests that at least 2 entries
(VIP, CYR61) of the predictor gene set are functionally involved in
phenotypical EMT induction by focal adhesion downstream (Wnt,
PI3K/AKT, MAPK) and immunosuppression (Figure 6). The
Table 3. The genes involved in immunosuppressive MDSCs
and TReg cells in terms of immunosuppression.
Genes Control
1 Cancer
1,2
Fold-change
(Cancer/Control)
CD4 2.589 3.561 1.962
CD25 (IL2RA) 5.651 6.879 2.342
FOXP3 3.882 7.199 9.966
TGF-b (TGFB1) 7.841 9.229 2.617
IFN-c (IFNG) 3.838 4.241 1.322
IL-10 (IL10) 4.784 5.887 2.148
CTLA-4 (CTLA) 5.460 7.398 3.832
PD-1 (PDCD1) 6.065 7.161 2.138
PD-L1 (CD274) 7.135 7.770 1.553
ARG1 3.079 4.004 1.899
CD11c (ITGAX) 6.553 7.747 2.288
CD11b (ITGAM) 5.757 6.854 2.139
CD33 4.567 5.470 1.870
CD34 7.162 8.798 3.108
FUT4 10.132 9.587 0.685
FUT9 2.141 3.585 2.721
Galectin-1 (LGALS1) 11.273 12.507 2.352
IL-6 5.976 7.342 2.578
IL-10 4.784 5.887 2.148
IDO (INDO, IDO1) 7.665 8.774 2.157
The majority of genes except FUT4 were up-regulated in the CRC patients.
1The value is the median of the log2-scaled expressions of the group.
2It is the normal-appearing mucosa in the CRC patients.
doi:10.1371/journal.pone.0031685.t003
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patients suggests that a subpopulation of cells in the mucosa have
experienced intrinsic transformation toward atypical or cancerous
phenotypes. Furthermore, potential atypical cells may survive
against immune cells by utilizing immunosuppressive cytokines
(e.g., VIP, TGF-b). Promotion of such an intrinsic survival
environment in the apparently normal mucosa is closely aligned
with the clinical observation of a field change [31], which refers to
proliferation and anti-apoptotic activity in apparently normal
mucosa adjacent to tumor. In the process of immunosuppression,
the immunosuppressive cytokines VIP (a member of the predictor
gene set) and TGF-b may be highly involved in the dynamics
between potential atypical cells and immune cells via paracrine
signaling (Figure 6). Our study suggests the co-occurrence of EMT
and immunosuppression [36] even in normal-appearing mucosa in
early-onsetCRCpatients.Finally,ourbiologicalsuggestionneedsto
be validated experimentally in future studies on early-onset CRC in
terms of dedifferentiation or differentiation, which is underscored in
EMT and immunosuppression.
Materials and Methods
Data
Gene expression data for early-onset CRCs were downloaded from
NCBI GEO (www.ncbi.nlm.nih.gov/geo/); the dataset identifier is
GSE4107 [3]. This dataset consists of data for 12 CRC patients and
10 healthy controls. Normal-appearing mucosa adjacent to tumor had
been obtained from the CRC patients and normal mucosa obtained
from the healthy controls. The predictor gene set was derived from
comparison between the normal-appearing mucosa from the cancer
patients and the normal mucosa from the controls. Of note, the
patients did not have FAP or HNPCC. We obtained prior regulation
information from KEGG [5].
Decomposition of the KEGG pathways into linear
subpathways
For simplicity, all the pathways of interest were divided into
linear subpathways by modifying the CPAN Paths::Graph library
(search.cpan.org/,cavasquez/Paths-Graph/Graph.pm) (Figure 2).
The linear subpathway is a sequence of linearly connected gene
entities from root node to leaf node. The root nodes are generally
membrane receptors, their ligands, and so on. The leaf nodes are
usuallytranscriptionfactorsand signalinginitiatorstowardthe other
pathways. We extracted as many linear subpathways as possible,
considering multiple gene assignments of each node.
Rules for gene expression and edge information of KEGG
Our goal was to identify subpathways in which gene expression
agreed withprior regulationinformation (e.g., activation,inhibition)
Table 4. The genes involved in EMT.
Functions Genes Control
1 Cancer
1,5 Fold-change
2
Matrix proteases
3 MMP2 5.265 6.865 3.031
MMP3 6.463 6.371 0.938
MMP9 9.667 11.131 2.758
MMP10 3.641 5.181 2.908
MMP11 4.321 5.659 2.529
MMP13 3.995 4.250 1.194
MMP14 6.383 7.259 1.836
MMP16 5.137 6.288 2.220
Invasion molecules
3 TWIST1 6.545 7.501 1.939
SLUG (SNAI2) 8.798 9.373 1.489
SDF-1 (CXCL12) 10.649 12.545 3.721
Epithelial markers
3 E-cadherin (CDH1) 10.753 8.291 0.181
TJP1 8.178 8.657 1.394
Mesenchymal markers
3 N-cadherin (CDH2) 5.029 7.526 5.645
Vimentin (VIM) 13.016 14.382 2.577
Transcriptional repressor of E-cadherin
4 FOXC2 5.710 7.498 3.453
SNAI1 5.762 7.511 3.362
SLUG 8.798 9.373 1.489
TWIST1 6.545 7.501 1.939
ZEB2 (ZFHX1B) 6.015 7.734 3.293
ZEB1 (TCF8) 6.731 8.026 2.453
FOXC1 6.877 7.375 1.412
GSC 4.048 3.781 0.831
The majority of the genes’ expressions, except GSC, TJP1 and MMP3, indicate further malignant development of the early onset cancer group. Surprisingly, E-cadherin
was down-regulated by more than 5 fold in the cancer patients.
1The value is the median of log2-scaled expressions of the group.
2The value is the fold-change of the cancer samples over the healthy controls.
3The genes refer to Knutson et al. [36].
4The genes refer to Polyak et al. [9].
5It is the normal-appearing mucosa in the CRC patients.
doi:10.1371/journal.pone.0031685.t004
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KEGG pathways was considered to be prior knowledge. Edge types
in KEGG represent regulations between the connected entities. We
simplified the edges into only 2 types: activation and repression. We
also assumed rules for matching an edge type of 2 adjacent entities
to their gene expression changes (Figure 1A) [44]. Given a
subpathway, we identified the longest consecutive segment
beginning from its leaf node; the segment had to satisfy the assumed
rules. The segment is referred to as a ‘‘well-defined subpathway’’ in
terms of gene expression data and prior knowledge (Figure 1B).
Further mathematical representation is also described below
detailing how we obtained the well-defined subpathway.
Given a subpathway with the number of nodes (genes) p,
the leaf node was set to G1 and the root node to Gp. The node Gi
had its binary representation (bi) of a fold-change (fi) for cancer over
control that was obtained from gene expression data. If fi.1, then bi
was +1, otherwise it was 21. The prior edge type ei between the
source node Gi+1 and the sink node Gi was either +1 (activation) or
21(repression)(Figures1Band 7).Theexpressionei6bi6bi+1should
have been equal to 1 if the expression matched with the regulations
under the rule. Again, edge information ei was derived from the
prior knowledge from KEGG, and fi and bi were derived from gene
expression data. In summary, the number of nodes (n) of a well-
defined subpathway was defined as follows:
Figure 7. The example of determination of the well-defined subpathway from a subpathway.
doi:10.1371/journal.pone.0031685.g007
Figure 6. Summary of functional roles of the predictor gene set in terms of EMT and immunosuppression. The two elements (VIP,
CYR61) of the predictor gene set can adjust the local immune system and induce malignant phenotype transformation via EMT.
doi:10.1371/journal.pone.0031685.g006
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(
The function I(?) represents the indicator function and the function
R(?) is a penalizing term that prevents probing progression from the
leaf node to the root node when prior edge information and
expression data did not agree with the rules. Figure 7 shows an
example of identification of the well-defined subpathway using the
previous equation, given a subpathway. It is noted that mathemat-
ical notation is also used throughout the manuscript.
Statistical analysis
In this section, we describe a statistical model to determine
significance for the well-defined subpathways. We conceptually
divided the well-defined subpathway into 3 components referred
to as node score (Fnode), edge score (Fedge), and score for the
number of nodes (Fnum), ultimately in order to define a total score
(Ftotal) of the well-defined subpathway. We designed Ftotal such that
the more differentially expressed genes agreed with the rule
(Figure 1A) in the well-defined subpathway, the less Ftotal was
equal to. Fnode represents the differential expression of the entries,
Fedge represents the regulation among the adjacent entries, and
Fnum represents length normalization. Fnum, a normalization factor
for n (the number of nodes in the well-defined subpathway), is
necessary because the longer n was, the less Ftotal was when
different well-defined subpathways were compared. In the text
below, we describe the biological rationale and mathematical
representation for the scores.
Before providing further explanation, we must define the terms
source node and sink node. That is, given edge en2i, the upstream
node Gn2(i21) is called a source node, whereas the downstream
node Gn2i is called a sink node (Figure 1A, B).
Typical expression analysis schemes focus only on highly
differentially expressed genes under a certain cutoff (e.g., p-value),
but it is important to consider that signaling proteins of an
activated or repressed pathway involved in phenotype differences
might not be changed drastically at the expression-level [45]. In
other words, employing strict cutoff usage in gene expression data
involves difficulties in uncovering signal cascading flows because
some entries within the signal cascading flows could be missed
under that cutoff. In contrast, Fnode does not filter out low
differential expression with an arbitrary condition because the p-
values of all the entries within the well-defined subpathway are
considered.
Fnode: P
n
i~1
p(Gi),
where n is the number of nodes in the well-defined subpathway
and p(?)i sap-value of a gene in a two-sample t-test between the
cancer and control groups. Therefore, the node score contains
both high and low differential expressions without a strict cutoff.
Fedge reflects edge information (e.g., activation, inhibition)
between 2 adjacent entries and derives from a joint distribution
of activities of a source node and its corresponding sink node. The
basic idea of Fedge is that, given a source node activity of edge en2i,
its corresponding sink node activity is expected to be highly dys-
regulated, which indicates a rare event. Therefore, Fedge follows,
by nature, the first-order Markov chain property in which a
current event depends only on its predecessor because we assume
that Gn2i is only regulated by its direct upstream source node
Gn2(i21) of edge en2i.
In Figure 1A, we used fold-changes to determine whether the
edge information complied with gene expression. The activities
around the edge were thus measured from fold-changes in cancer
over control, and the activity was simply transformed into a log2
scale for better normality. In other words, log2-transformed fold-
changes of the 2 adjacent nodes were used as a measure of edge
information, and the joint distribution of a source node and its sink
node was calculated.
According to the first-order Markov chain property, we can
simply define Fedge as the products of conditional probabilities
log2(fn2i)|log2(fn2(i21)) from i=1 to n21 multiplied by a prior
Pr(log2(fn)). The conditional probabilities can be derived from the
joint distribution of the pair (log2(fold-change of the source node),
log2(fold-change of the sink node)), which is assumed to be a
bivariate normal distribution.
Fedge:Pr(log2fn) P
n{1
i~1
Pr(log2fn{iDlog2fn{(i{1)),
where n is the number of nodes in the well-defined subpathway.
To determine the joint distribution of the pair (log2(fold-change
of the source node), log2 (fold-change of the sink node)), we
extracted all the edges from the KEGG XML files (KGML files)
and obtained the source nodes and their corresponding sink nodes
from the edges. The log2-transformed fold-changes (e.g., a pair
(log2fn2(i21), log2fn2i)) of the cancer group over the control group
for the pair source node and sink node were obtained from the
microarrays.
log2 (fold change of the source node)
log2 (fold change of the sink node)
 !
*
MVN
0:4927
0:4355
 !
,
1:354 0:03152
0:03152 1:112
 !  !
:
Prior probability (e.g., Pr(log2fn)) of the log2-transformed fold-
change of a gene was assumed to be a univariate normal
distribution, which is obtained from the log2-transformed fold-
changes of all the entries belonging to the KEGG pathways.
Fnum was derived from a random graph model. We used an R
statistical package library ‘‘igraph’’ [46] to make 1,000 simulated
randomgraphswiththenumber ofnodessetto200andthe number
of edges to 100. We reduced the random graphs into all linearly
connected paths from roots to leaves, and the distribution of the
number of edges for the paths was calculated (Figure S8). Fnum was
borrowed from the distribution of the number of edges from the
random graphs. Subsequently, n (the number of connected nodes in
the well-defined subpathway) was considered as equal to 1 plus the
number of edges in the well-defined subpathway.
Finally, we defined Ftotal as follows:
Ftotal:Fnode|Fedge|Fnum:
For computational simplicity, we used its minus natural logarithm
of Ftotal as a statistic instead: S~{lnFtotal, S[½0,?):
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We obtained the null distribution of S by generating 1,000,000
permuted samples. Each permuted sample was generated by
shuffling the sample labels in the microarrays. For each
permutation, we applied the rules to the original subpathways in
order to redefine their well-defined subpathways, and then
performed the same procedures discussed above. The p-value
was obtained empirically by computing Pr(S$s), where s was the
observed value in the original gene expression data.
We also provide detailed information of all 4,644 well-defined
subpathways in Table S4 (xls format), including their p-values,
FDR q-values, and regulation information.
Supporting Information
Figure S1 Statistic S, p-value and multiple comparison
correction. A. S versus 2log10(p-value) in the 4,644 well-defined
subpathways. The x-axis represents 21og10(p-value) and the y-axis
S. B. 2log10(p-value) versus FDR q-value. The x-axis is FDR q-
value and the y axis 2log10(p-value). The FDR q-values as well as
p-values were summarized in Table S4 (see the sixth and eighth
columns in Table S4).
(DOC)
Figure S2 KEGG pathways containing the top 30% well-
defined subpathways. The x-axis represents the number of the
significant well-defined subpathways corresponding to the KEGG
pathway.
(DOC)
Figure S3 Pathways in cancer (KEGG hsa05200). Red
boxes are activated in the CRC patients over the healthy controls.
Green boxes are down-regulated in the CRC patients.
(DOC)
Figure S4 MAPK signaling pathway (KEGG hsa04010).
Red boxes are activated in the CRC patients over the healthy
controls. Green boxes are down-regulated in the CRC patients.
(DOC)
Figure S5 Wnt signaling pathway (KEGG hsa04310). Red
boxes are activated in the CRC patients over the healthy controls.
Green boxes are down-regulated in the CRC patients.
(DOC)
Figure S6 Neutrophin signaling pathway (KEGG
hsa04722). Red boxes are activated in the CRC patients over
the healthy controls. Green boxes are down-regulated in the CRC
patients.
(DOC)
Figure S7 The input item options used in Figure 5. The
item ‘‘Gene/Protein’’ in the PubGene input webpage is CYR61,
FOS, FOSB, UCHL1, VIP, EGR1, KRT24, PTK2, ITGB5,
IFNG, FAS, and FASLG. The item ‘‘Biological term’’ in the
webpage is colorectal cancer.
(DOC)
Figure S8 Distribution of the number of edges in the
linearly connected paths based on the 1,000 simulated
random graphs. The x-axis represents the number of the edges,
and the y-axis probability.
(DOC)
Table S1 The numeric identifiers of the well-defined
subpathways used for the functional discussion and
visualization of the six KEGG pathways. The number indicates
column ‘‘No.’’in Table S4 (xlsformat).Readerssee all the information
of significance, regulation flow, fold-change and so on from Table S4.
(DOC)
Table S2 We fed the entries in Table 1 into PubGene in
order to validate literature-based associations between our
result and the term ‘‘colorectal cancer’’. The listed genes have
no direct co-occurrence with the term ‘‘colorectal cancer’’ according
to PubGene. The majority (79%) of the entries in Table 1 have
publication-based evidences. It is noted that CYR61 and FASLG in
Table 1 were not included in the PubGene validation analysis because
the two genes were not reported in our statistical analysis.
(DOC)
Table S3 Comparison with our method and GSEA. We
set the Vogelstein cancer-related pathways [13] (first column) as a
gold standard. We inspected overlap between the gold standard
and each method result. As a result, our method performed better
than GSEA. The second column represents KEGG pathways
corresponding to the first column. (O: overlap, X: no overlap)
(DOC)
Table S4 Detailed information of all the 4,644 well-
defined subpathways. No.: numeric identifier for the well-
defined subpathway, KEGG: its corresponding KEGG pathway
identifier, Title: KEGG pathway name, WellDefinedSubpathway-
WithFoldChange: signaling flow of the well-defined subpathway
with fold-change of the cancer patients over the healthy control,
NumNodes: the number of entries, P-value: nominal p-value, S:
our statistic, FDR (q-value): adjusted p-value, 2log10(P-value):
minus logarithm of p-value with base 10.
(XLS)
Table S5 The expressions of TGF-bs and their receptors
were summarized. Majority of the genes were up-regulated in
the cancer except TGFBR1.
(DOC)
Appendix S1 The additional analysis for GSEA compar-
ison and independent dataset validation.
(DOC)
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